Lupin is currently trading at Rs. 1439.00, up by 10.30 points or 0.72% from its previous closing of Rs. 1428.70 on the BSE.
The scrip opened at Rs. 1440.00 and has touched a high and low of Rs. 1442.00 and Rs. 1437.85 respectively. So far 2,442 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1500.00 on 24-Nov-2014 and a 52 week low of Rs. 855.00 on 30-Jan-2014.
Last one week high and low of the scrip stood at Rs. 1442.00 and Rs. 1392.00 respectively. The current market cap of the company is Rs. 64,664.00 crore.
The promoters holding in the company stood at 46.69% while Institutions and Non-Institutions held 42.71% and 10.60% respectively.
Pharma Major Lupin has received tentative approval for its Darunavir Ethanolate Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg and 800 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Janssen Products, LP (Janssen) Prezista Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg.
The company’s Darunavir Ethanolate Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg are the AB-rated generic equivalents of Janssen’s Prezista tablets and are indicated Lupin’s Darunavir Tablets is indicated for the treatment of HIV-1 infections. Prezista Tablets had annual U.S sales of $ 1.2 billion.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1777.65 |
| Dr. Reddys Lab | 1194.55 |
| Cipla | 1465.65 |
| Lupin | 2043.30 |
| Zydus Lifesciences | 944.25 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
